Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

The phase 2b AMP trials are testing whether the broadly neutralising antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switzerland. We used nonlinear mixed effects modelling of longi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EBioMedicine
Autori principali: Huang, Yunda, Naidoo, Logashvari, Zhang, Lily, Carpp, Lindsay N., Rudnicki, Erika, Randhawa, April, Gonzales, Pedro, McDermott, Adrian, Ledgerwood, Julie, Lorenzo, Margarita M.Gomez, Burns, David, DeCamp, Allan, Juraska, Michal, Mascola, John, Edupuganti, Srilatha, Mgodi, Nyaradzo, Cohen, Myron, Corey, Lawrence, Andrew, Philip, Karuna, Shelly, Gilbert, Peter B., Mngadi, Kathryn, Lazarus, Erica
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2021
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841500/
https://ncbi.nlm.nih.gov/pubmed/33493795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.103203
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi